A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study

David L. Tait, John A. Blessing, James S. Hoffman, Kathleen N. Moore, Nick M. Spirtos, Jason A. Lachance, Jacob Rotmensch, David S. Miller

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: The study aims to evaluate the anti-tumor activity and toxicity of gemcitabine in patients with persistent or recurrent endometrial carcinoma. Methods: Patients with advanced or recurrent carcinoma of the endometrium previously treated with one chemotherapy regimen were treated on a phase II trial conducted by the Gynecologic Oncology Group (GOG). Gemcitabine was administered as an intravenous infusion at a dose of 800 mg/m2 over 30 min on days 1 and 8 every 21 days. Results: Twenty-four patients were entered by 11 GOG member institutions. One patient was ineligible due to wrong primary tumor. A total of ninety 21-day cycles of therapy were administered with 35% of patients receiving four or more cycles. All patients had been previously treated with a platinum-based regimen. One patient had a partial response (4%), nine had stable disease (39%), and twelve had increasing disease (52%). The median progression-free survival was 1.7 months. Treatment was generally well tolerated with only 22% of patients experiencing grade 3 or grade 4 hematologic toxicity. There was one treated-related death due to pulmonary toxicity. Conclusion: Gemcitabine has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested.

Original languageEnglish (US)
Pages (from-to)118-121
Number of pages4
JournalGynecologic Oncology
Volume121
Issue number1
DOIs
StatePublished - Apr 2011

Fingerprint

gemcitabine
Endometrial Neoplasms
Therapeutics
Platinum
Intravenous Infusions
Disease-Free Survival
Neoplasms
Appointments and Schedules

Keywords

  • Endometrial carcinoma
  • Gemcitabine
  • Gemzar
  • Gynecologic Oncology Group

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma : A gynecologic oncology group study. / Tait, David L.; Blessing, John A.; Hoffman, James S.; Moore, Kathleen N.; Spirtos, Nick M.; Lachance, Jason A.; Rotmensch, Jacob; Miller, David S.

In: Gynecologic Oncology, Vol. 121, No. 1, 04.2011, p. 118-121.

Research output: Contribution to journalArticle

Tait, David L. ; Blessing, John A. ; Hoffman, James S. ; Moore, Kathleen N. ; Spirtos, Nick M. ; Lachance, Jason A. ; Rotmensch, Jacob ; Miller, David S. / A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma : A gynecologic oncology group study. In: Gynecologic Oncology. 2011 ; Vol. 121, No. 1. pp. 118-121.
@article{0335366df4fb452c837beee1340954b3,
title = "A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study",
abstract = "Objective: The study aims to evaluate the anti-tumor activity and toxicity of gemcitabine in patients with persistent or recurrent endometrial carcinoma. Methods: Patients with advanced or recurrent carcinoma of the endometrium previously treated with one chemotherapy regimen were treated on a phase II trial conducted by the Gynecologic Oncology Group (GOG). Gemcitabine was administered as an intravenous infusion at a dose of 800 mg/m2 over 30 min on days 1 and 8 every 21 days. Results: Twenty-four patients were entered by 11 GOG member institutions. One patient was ineligible due to wrong primary tumor. A total of ninety 21-day cycles of therapy were administered with 35{\%} of patients receiving four or more cycles. All patients had been previously treated with a platinum-based regimen. One patient had a partial response (4{\%}), nine had stable disease (39{\%}), and twelve had increasing disease (52{\%}). The median progression-free survival was 1.7 months. Treatment was generally well tolerated with only 22{\%} of patients experiencing grade 3 or grade 4 hematologic toxicity. There was one treated-related death due to pulmonary toxicity. Conclusion: Gemcitabine has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested.",
keywords = "Endometrial carcinoma, Gemcitabine, Gemzar, Gynecologic Oncology Group",
author = "Tait, {David L.} and Blessing, {John A.} and Hoffman, {James S.} and Moore, {Kathleen N.} and Spirtos, {Nick M.} and Lachance, {Jason A.} and Jacob Rotmensch and Miller, {David S.}",
year = "2011",
month = "4",
doi = "10.1016/j.ygyno.2010.11.027",
language = "English (US)",
volume = "121",
pages = "118--121",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma

T2 - A gynecologic oncology group study

AU - Tait, David L.

AU - Blessing, John A.

AU - Hoffman, James S.

AU - Moore, Kathleen N.

AU - Spirtos, Nick M.

AU - Lachance, Jason A.

AU - Rotmensch, Jacob

AU - Miller, David S.

PY - 2011/4

Y1 - 2011/4

N2 - Objective: The study aims to evaluate the anti-tumor activity and toxicity of gemcitabine in patients with persistent or recurrent endometrial carcinoma. Methods: Patients with advanced or recurrent carcinoma of the endometrium previously treated with one chemotherapy regimen were treated on a phase II trial conducted by the Gynecologic Oncology Group (GOG). Gemcitabine was administered as an intravenous infusion at a dose of 800 mg/m2 over 30 min on days 1 and 8 every 21 days. Results: Twenty-four patients were entered by 11 GOG member institutions. One patient was ineligible due to wrong primary tumor. A total of ninety 21-day cycles of therapy were administered with 35% of patients receiving four or more cycles. All patients had been previously treated with a platinum-based regimen. One patient had a partial response (4%), nine had stable disease (39%), and twelve had increasing disease (52%). The median progression-free survival was 1.7 months. Treatment was generally well tolerated with only 22% of patients experiencing grade 3 or grade 4 hematologic toxicity. There was one treated-related death due to pulmonary toxicity. Conclusion: Gemcitabine has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested.

AB - Objective: The study aims to evaluate the anti-tumor activity and toxicity of gemcitabine in patients with persistent or recurrent endometrial carcinoma. Methods: Patients with advanced or recurrent carcinoma of the endometrium previously treated with one chemotherapy regimen were treated on a phase II trial conducted by the Gynecologic Oncology Group (GOG). Gemcitabine was administered as an intravenous infusion at a dose of 800 mg/m2 over 30 min on days 1 and 8 every 21 days. Results: Twenty-four patients were entered by 11 GOG member institutions. One patient was ineligible due to wrong primary tumor. A total of ninety 21-day cycles of therapy were administered with 35% of patients receiving four or more cycles. All patients had been previously treated with a platinum-based regimen. One patient had a partial response (4%), nine had stable disease (39%), and twelve had increasing disease (52%). The median progression-free survival was 1.7 months. Treatment was generally well tolerated with only 22% of patients experiencing grade 3 or grade 4 hematologic toxicity. There was one treated-related death due to pulmonary toxicity. Conclusion: Gemcitabine has minimal activity in the treatment of recurrent or persistent endometrial carcinoma at the dose and schedule tested.

KW - Endometrial carcinoma

KW - Gemcitabine

KW - Gemzar

KW - Gynecologic Oncology Group

UR - http://www.scopus.com/inward/record.url?scp=79952819390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952819390&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2010.11.027

DO - 10.1016/j.ygyno.2010.11.027

M3 - Article

C2 - 21159366

AN - SCOPUS:79952819390

VL - 121

SP - 118

EP - 121

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -